Page last updated: 2024-12-06

xylamidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

xylamidine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID22951
CHEMBL ID2110630
SCHEMBL ID2107805
MeSH IDM0047750

Synonyms (16)

Synonym
PDSP2_001336
PDSP1_001352
xylamidine
benzeneethanimidamide, n-(2-(3-methoxyphenoxy)propyl)-3-methyl-
n'-[2-(3-methoxyphenoxy)propyl]-2-(3-methylphenyl)ethanimidamide
unii-ny0pc84nzk
6443-50-1
ny0pc84nzk ,
n-(2-(m-methoxyphenoxy)propyl)-2-m-tolylacetamidine
SCHEMBL2107805
CHEMBL2110630
benzeneethanimidamide, n-[2-(3-methoxyphenoxy)propyl]-3-methyl-
Q8045338
DTXSID90863843
n-(2-(3-methoxyphenoxy)propyl)-2-(m-tolyl)acetimidamide
AKOS040754478

Research Excerpts

Treatment

Pretreatment with xylamidine tosylate, a 5-HT2 receptor antagonist that does not cross the blood-brain barrier, blocked the pressor response to i.v.

ExcerptReferenceRelevance
"xylamidine pretreatment. These data suggest that the central 5-HT2 receptor may subserve pressor function in rats."( Role of central serotonergic (5-HT2) receptor in blood pressure regulation in rats.
Hatayama, Y; Ishii, T; Kajiwara, N; Kobayashi, Y; Koike, J; Kurumatani, H; Kushiro, T; Yokoyama, H, 1988
)
1
"Pretreatment with xylamidine tosylate, a 5-HT2 receptor antagonist that does not cross the blood-brain barrier, blocked the pressor response to i.v., but not i.c.v., administration of equivalent doses of DOI."( Central and peripheral injections of the 5-HT2 agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, modify cardiovascular function through different mechanisms.
Dedeoğlu, A; Fisher, LA, 1991
)
0.6

Dosage Studied

ExcerptRelevanceReference
"05) by the greatest dosage of LY 53,857 (LY: 5-HT1C and 5-HT2 antagonist) (1."( Serotonergic agonists and antagonists affect endurance performance in the rat.
Ahlborn, EN; Bailey, SP; Davis, JM, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (48.28)18.7374
1990's12 (41.38)18.2507
2000's3 (10.34)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]